Proqr Therapeutics N.V. (PRQR) — 6-K Filings

6-K Filings (29)

• 6-K Filing — May 4, 2026
• 6-K Filing — Apr 30, 2026
• 6-K Filing — Apr 8, 2026
• ProQR Therapeutics Files Routine 6-K Report on March 25, 2026 — Mar 25, 2026
  ProQR Therapeutics N.V. filed a 6-K on March 25, 2026, indicating a routine report for foreign issuers. This filing, with accession number 0001104659-26-034158,
• ProQR Therapeutics Files 6-K Report — Nov 6, 2025 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on November 6, 2025, reporting its financial information as of September 30, 2025. The filing is a report of a foreign
• ProQR Therapeutics Advances AX-0810 Towards Clinic — Nov 3, 2025 Risk: medium
  On November 3, 2025, ProQR Therapeutics N.V. hosted a virtual event to discuss the progress of their drug candidate AX-0810. The event focused on establishing t
• ProQR Therapeutics Gets CTA Approval for AX-0810 — Oct 20, 2025 Risk: medium
  On October 20, 2025, ProQR Therapeutics N.V. announced it received Clinical Trial Application (CTA) authorization for its drug candidate AX-0810. The company al
• ProQR Therapeutics Files 6-K Report — Aug 7, 2025 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on August 7, 2025, reporting its financial information as of June 30, 2025. The filing is a report of a foreign private
• ProQR Therapeutics Submits CTA for AX-0810 Phase 1 Study — Jun 26, 2025 Risk: medium
  On June 26, 2025, ProQR Therapeutics N.V. announced the submission of a Clinical Trial Application (CTA) for a Phase 1 study of its investigational drug AX-0810
• ProQR Therapeutics Holds 2025 Annual Shareholder Meeting — Jun 3, 2025 Risk: low
  ProQR Therapeutics N.V. held its 2025 annual general meeting of shareholders on June 3, 2025. The meeting took place at the offices of Allen Overy Shea. The fil
• ProQR Therapeutics Files 6-K for Q1 2025 — May 8, 2025 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on May 8, 2025, reporting its financial information as of March 31, 2025. The company, based in Leiden, The Netherlands
• ProQR Therapeutics Sets Annual Shareholder Meeting for June 3 — May 1, 2025 Risk: low
  ProQR Therapeutics N.V. announced on May 1, 2025, that its Annual General Meeting of Shareholders will be held on June 3, 2025. The company also made certain in
• ProQR Therapeutics Appoints New CFO and CMO — Apr 14, 2025 Risk: low
  On April 14, 2025, ProQR Therapeutics N.V. announced the appointment of a new Chief Financial Officer (CFO) and Chief Medical Officer (CMO) to bolster its leade
• ProQR Therapeutics Files 6-K with Results Announcement — Mar 13, 2025 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on March 13, 2025, to furnish a press release dated the same day. This press release announces the company's results, t
• ProQR Therapeutics Secures $8.1M Funding — Dec 11, 2024 Risk: medium
  On December 11, 2024, ProQR Therapeutics N.V. announced it secured $8.1 million in new funding from the Rett Syndrome Research Trust. This funding is intended t
• ProQR Therapeutics Appoints New CFO — Dec 10, 2024 Risk: low
  On December 10, 2024, ProQR Therapeutics N.V. announced the appointment of Peter van der Kuy as its new Chief Financial Officer, effective January 1, 2025. Van
• ProQR Therapeutics Closes $100M Public Offering — Dec 5, 2024 Risk: medium
  On December 5, 2024, ProQR Therapeutics N.V. announced the closing of its previously announced underwritten public offering. The company successfully raised app
• ProQR Therapeutics Files 6-K for Q3 2024 — Nov 7, 2024 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on November 7, 2024, reporting its financial results for the period ending September 30, 2024. The company, based in Le
• ProQR Therapeutics N.V. Enters Underwriting Agreement — Oct 25, 2024 Risk: medium
  On October 22, 2024, ProQR Therapeutics N.V. entered into an underwriting agreement. This filing is a report of a foreign private issuer pursuant to Rule 13a-16
• ProQR Therapeutics Files 6-K Report — Aug 8, 2024 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on August 8, 2024, reporting its financial information as of June 30, 2024. The filing is a report of a foreign private
• ProQR Therapeutics N.V. Holds 2024 Annual General Meeting — May 22, 2024 Risk: low
  ProQR Therapeutics N.V. held its 2024 annual general meeting of shareholders on May 22, 2024. The meeting results, which are the subject of this 6-K filing, wer
• ProQR Therapeutics Files 6-K for Q1 2024 Results — May 9, 2024 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on May 9, 2024, reporting its financial results for the period ending March 31, 2024. The company, based in Leiden, The
• ProQR Therapeutics Announces Preclinical Data for AX-0810 — May 8, 2024 Risk: medium
  On May 8, 2024, ProQR Therapeutics N.V. announced positive preclinical proof-of-concept data for its AX-0810 Axiomer RNA editing therapy. The data demonstrated
• ProQR Therapeutics Nominates Board Member, Sets Shareholder Meeting — Apr 23, 2024 Risk: low
  ProQR Therapeutics N.V. announced on April 23, 2024, that it has nominated Martin Maier, PhD, to its Board of Directors. The company also announced that its Ann
• ProQR Therapeutics Wins IP Challenge — Apr 19, 2024 Risk: low
  On April 19, 2024, ProQR Therapeutics N.V. announced the successful defense of a new challenge to its Axiomer™ intellectual property portfolio. This defense rei
• ProQR Therapeutics Files 6-K, Announces Results — Mar 13, 2024 Risk: low
  ProQR Therapeutics N.V. filed a Form 6-K on March 13, 2024, to furnish a press release dated March 13, 2024. This press release announces the company's results,
• ProQR's Japanese Axiomer Patent Upheld After Opposition — Feb 15, 2024 Risk: low
  ProQR Therapeutics N.V. announced on February 15, 2024, that its Japanese Axiomer™ Patent was upheld following an opposition. This successful defense of its int
• ProQR Highlights New Axiomer™ RNA Editing Data at Deaminet 2024 — Jan 19, 2024
  On January 19, 2024, ProQR Therapeutics N.V. filed a 6-K announcing a press release titled, "ProQR Highlights New Platform Data from Presentation on Axiomer™ RN
• ProQR Partners with Rett Syndrome Research Trust on Axiomer™ RNA Editing — Jan 5, 2024
  On January 5, 2024, ProQR Therapeutics N.V. announced a collaboration with the Rett Syndrome Research Trust, focusing on ProQR's Axiomer™ RNA editing technology

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX